Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies


The JAK2-V617F mutation is prevalent in almost all patients with polycythemia vera (PV) and about half of the cases of essential thrombocythaemia (ET) and primary myelofibrosis (PMF). A different allele burden in these entities has long been noticed, but little is known about its distribution among the neoplastic hematopoietic cell lineages within the bone marrow. We conducted a microdissection study of JAK2-V617F-mutated myeloproliferative neoplasms (MPN); 10 cases each of ET, PV, and PMF, with separate analysis of the JAK2 mutation status in three hematopoietic cell lines (i.e., megakaryo-, granulo-, and erythropoiesis). Different numbers of cell lineages harboring the JAK2-V617F mutation were found, being the lowest in ET (17/30), higher in PV (24/30) and in PMF (22/30). The megakaryopoiesis was the most commonly mutated cell lineage (24/30 cases). By analyzing microdissectates we were able to demonstrate a different allele burden of the JAK2-V617F mutation in the megakaryo-, erythro-, and granulopoiesis within the bone marrow of a given case of MPN. We demonstrated differences in the number of mutated cell lineages. The different mutation status may contribute to the different phenotypes of ET, PV, and PMF.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    Skoda R (2007) The genetic basis of myeloproliferative disorders. Hematology 2007:1–9

  2. 2.

    Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790

  3. 3.

    Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168

  4. 4.

    Hussein K, Bock O, Kreipe H (2007) Histologic and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathol Biol 74:72–80

  5. 5.

    Jamieson CHM, Gotlib J, Durocher JA et al (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci 103:6224–6229

  6. 6.

    Ishii T, Bruno E, Hoffman R et al (2006) Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 108:3128–3134

  7. 7.

    Pardanani A, Lasho TL, Finke C et al (2007) Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 25:2358–2362

  8. 8.

    Delhommeau F, Dupont S, Tonetti C et al (2007) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109:71–77

  9. 9.

    Beer PA, Jones AV, Bench AJ et al (2009) Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 144:904–908

  10. 10.

    Scott LM, Scott MA, Campbell PJ et al (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108:2435–2437

  11. 11.

    Jamal R, Belisle C, Lessard MC et al (2008) Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia 22:1472–1474

  12. 12.

    Antonioli E, Guglielmelli P, Poli G et al (2007) Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood 110:4620–4621

  13. 13.

    Larsen TS, Pallisgaard N, Møller MB et al (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis—impact on disease phenotype. Eur J Haematol 79:508–515

  14. 14.

    Alison RM, Donna MW, Ophelia R et al (2008) Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 36:1480–1486

  15. 15.

    Antonioli E, Guglielmelli P, Poli G et al (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93:41–48

  16. 16.

    Alessandra C, Guido F, Elisabetta A et al (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37:1016–1021

  17. 17.

    Passamonti F, Rumi E, Pietra D et al (2006) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 107:3676–3682

  18. 18.

    Stein BL, Williams DM, Rogers O et al (2011) Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol 39:95–101

  19. 19.

    Swerdlow SH, Campo E, Harris NL et al (ed) (2008) World Health Organization classification of tumours: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. IARC, Lyon

  20. 20.

    Kreft A, Weiß M, Wiese B et al (2003) Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. Ann Hematol 82:605–611

  21. 21.

    Hussein K, Brakensiek K, Büsche G et al (2007) Different involvement of the megakaryocytic linage by the JAK2 V617F mutation in polycythenia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Ann Hematol 86:245–253

  22. 22.

    Kreft A, Springer E, Lipka DB et al (2009) Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis. Acta Haematol 122:36–38

  23. 23.

    Kremer M, Horn T, Koch I et al (2008) Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol 32(6):928–935

  24. 24.

    Rohlin A, Wernersson J, Engwall Y et al (2009) Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques. Hum Mutat 30:1012–1020

  25. 25.

    Dupont S, Masse A, James C et al (2007) The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 110:1013–1021

  26. 26.

    Hussein K, Bock O, Theophile K et al (2009) JAK2V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37:1186–1193

  27. 27.

    Lambert JR, Everington T, Linch DC et al (2009) In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 114:3018–3023

  28. 28.

    Gattenlohner S, Serfling E, Einsele H et al (2008) Molecular insights into the morphology of myeloproliferative neoplasms using an in situ PCR assay specific for the JAK2 mutation V617F. Leukemia 23:196–199

  29. 29.

    Georgii A, Büsche G, Kreft A et al (1999) Histological classification and grading of bone marrow biopsies provides prognostic data at diagnosis in patients with chronic myeloproliferation. Haematologica 83(suppl 1):169–174

  30. 30.

    Kralovics R, Teo S-S, Li S et al (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108:1377–1380

  31. 31.

    Nussenzveig RH, Swierczek SI, Jelinek J et al (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 35:32–38

  32. 32.

    Theocharides A, Boissinot M, Girodon F et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110:375–379

  33. 33.

    Guglielmelli P, Barosi G, Pieri L et al (2009) JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica 94:144–146

  34. 34.

    Passamonti F, Rumi E, Pietra D et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24:1574–1579

  35. 35.

    Silver RT, Vandris K, Wang YL et al (2011) JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 35:177–182

  36. 36.

    Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 21:1952–1959

  37. 37.

    Vannucchi AM, Antonioli E, Guglielmelli P et al (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22:1299–1307

Download references

Conflict of interest statement

The authors declare that they have no conflict of interest.

Author information

Correspondence to Andreas Kreft.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kreft, A., Kindler, T., Springer, E. et al. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies. Virchows Arch 459, 521 (2011).

Download citation


  • MPN
  • JAK2-V617F mutation
  • Microdissection